-
Tytuł:
-
Serous endometrial intraepithelial carcinoma (SEIC): Current clinical practice in The Netherlands.
-
Autorzy:
-
Slaager C; Franciscus Gasthuis en Vlietland, Department of Obstetrics and Gynecology. Kleiweg 400, Rotterdam, The Netherlands. Electronic address: .
Hofhuis W; Franciscus Gasthuis en Vlietland, Department of Obstetrics and Gynecology. Kleiweg 400, Rotterdam, The Netherlands. Electronic address: .
Hoogduin K; Pathan BV. Kleiweg 400, Rotterdam, The Netherlands. Electronic address: .
Ewing-Graham P; Erasmus Medical Center, Department of Pathology. Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Electronic address: .
van Beekhuizen H; Erasmus MC Cancer Institute, Department of Gynecological Oncology. Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Electronic address: .
-
Źródło:
-
European journal of obstetrics, gynecology, and reproductive biology [Eur J Obstet Gynecol Reprod Biol] 2021 Oct; Vol. 265, pp. 25-29. Date of Electronic Publication: 2021 Aug 11.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Limerick : Elsevier Scientific Publishers
Original Publication: Amsterdam, Excerpta Medica.
-
MeSH Terms:
-
Carcinoma in Situ*/pathology
Cystadenocarcinoma, Serous*/pathology
Endometrial Neoplasms*/pathology
Endometrial Neoplasms*/therapy
Uterine Neoplasms*/pathology
Cohort Studies ; Female ; Humans ; Hysterectomy ; Lymph Node Excision ; Neoplasm Staging ; Netherlands/epidemiology
-
Contributed Indexing:
-
Keywords: Carcinoma in situ; Endometrial neoplasms; Serous endometrial intraepithelial carcinoma; Surgical techniques; Uterine neoplasms
-
Entry Date(s):
-
Date Created: 20210820 Date Completed: 20211005 Latest Revision: 20211005
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.ejogrb.2021.08.012
-
PMID:
-
34416579
-
Introduction: Serous endometrial intraepithelial carcinoma (SEIC) is a rare diagnosis, defined as an intraepithelial lesion with cells identical to serous type endometrial carcinoma. SEIC is considered to be potentially metastatic, however clear and robust data on prognosis are lacking, potentially leading to variability in clinical management.
Objective: The aim is to establish the opinion of gynecologists on the optimal management of patients with SEIC.
Methods: An online questionnaire with 15 multiple choice questions was sent to all gynecologists with expertise in gynecological oncology in 19 expert centers in The Netherlands.
Results: A total of 24 gynecologists participated. The majority of respondents (n = 18/24, 75%) do not consult a guideline regarding the treatment of SEIC. In current practice, 14 of the 24 respondents perform surgical staging in women with SEIC (58.3%) while seven choose hysterectomy with bilateral salpingo-oophorectomy (29.2%), and three (12.5%) have no firm preference. Eleven of the 14 respondents who perform a surgical staging procedure believe that this is certainly the optimal treatment. The majority of respondents have no firm opinion on whether lymph node sampling or lymph node dissection is preferable during surgical staging (n = 15/23, 65.2%). Most respondents do not give adjuvant therapy (n = 15/24, 62.5%), 25.0% recommend brachytherapy (n = 6/24). Follow-up is for 5 years in almost all cases (n = 23/24).
Conclusion: There is no consensus on the optimal surgical treatment and the use of adjuvant therapy for patients with SEIC. Our research team is therefore conducting a nationwide cohort study in which treatment modality, morbidity and survival will be evaluated.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
